Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03766126
Other study ID # 831619 (UPCC 35418)
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date December 6, 2018
Est. completion date December 3, 2033

Study information

Verified date April 2024
Source University of Pennsylvania
Contact EmergingMed
Phone 855-216-0098
Email PennCancerTrials@careboxhealth.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in Acute Myeloid Leukemia (AML) subjects.


Description:

This is a Phase 1 study to determine the safety, feasibility, and efficacy of CART123 cells following lymphodepleting chemotherapy in patients with relapsed/refractory AML. Subjects will be treated with a split dosing approach of CART123 cells (10% Day 0; 30% Day 1; 60% Day 2) for Cohort 1a/1b or a single IV administration of CART123 cells for Cohort 2. The total dose administered to each subject will be based on body weight obtained at the time of apheresis. Thus, the target total transduced dose, preceded by lymphodepleting chemotherapy, is 1-2x10^6 CART123 cells/kg for Cohort 1a, 5x10^6 CART123 cells/kg for Cohort 1b, or 2x10^6 CART-123 cells/kg for Cohort 2. The protocol-specified minimum acceptable dose for infusion is 1x10^5 CART123 cells/kg for all cohorts. It is recommended per routine clinical care, that all subjects with marrow aplasia at Day 28+/-5 undergo allogeneic hematopoietic cell transplantation (alloHCT) as a rescue strategy. If required, this procedure will be performed as part of routine care, outside of the scope of this research study, however subjects will continue to be followed on study. All subjects should therefore have a previously identified stem cell donor in order to participate in this study. Please see Section 6.8 for additional details. All subjects will be followed monthly for up to 6 months post the first CART123 cell infusion (Day 0). Thereafter subjects will be transitioned into LTFU for up to 15 years post infusion.


Recruitment information / eligibility

Status Recruiting
Enrollment 12
Est. completion date December 3, 2033
Est. primary completion date August 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or female subjects 18 years of age or older 2. Subjects with active acute myeloid leukemia (AML) with no available curative treatment options using currently available therapies. Specifically: 1. AML that has not achieved a complete remission or morphologic leukemia free state by ELN criteria (Döhner et al., 2017 Blood, 129(4):424-447); partial remission or refractory disease (including primary refractory) are eligible. Or: 2. AML relapsed following allogeneic stem cell transplantation (including MDS evolved to AML post-allogeneic stem cell transplantation). Note: morphologic relapse is not required; persistent/recurrent disease-associated molecular, phenotypic or cytogenetic abnormalities (measurable residual disease, MRD) at any time after allogeneic HCT is eligible 3. Subjects with relapsed disease after prior transplant must meet one of the following: a. Subjects with relapsed disease after prior allogeneic HCT (myeloablative or non-myeloablative) will be eligible if they meet all other inclusion criteria and i. Have no residual donor cells (by STR analysis on 2 occasions separated by at least 1 month), OR: ii. Donor cells are present but there is no active GVHD (>Gr II), subject does not require systemic immunosuppression and is more than 3 months from transplant, and at least 1 month off GVHD prophylaxis. b. Subjects with relapsed disease after prior autologous or syngeneic HCT will be eligible if they meet all other inclusion criteria and it has been more than 3 months from transplant. 4. Subjects must have a suitable stem cell donor available who may donate cells in the event the subject needs to undergo an allogeneic HCT. Donor may be matched or mismatched and must be found to be suitable according to the institution's standard criteria; donors must be fully cleared to proceed as the donor. 5. Satisfactory organ functions: 1. Creatinine = 1.6 mg/dl 2. ALT/AST must be =5 x upper limit of normal unless related to disease 3. Direct bilirubin or total bilirubin < 2.0mg/dl, unless subject has Gilbert's syndrome (=3.0 mg/dL); 4. Left ventricular ejection fraction = 40% as confirmed by ECHO/MUGA 6. ECOG Performance status 0-2. 7. Written informed consent is given. 8. No contraindications for leukapheresis. 9. Subjects of reproductive potential must agree to use acceptable birth control methods (as described in protocol Section 4.3). Exclusion Criteria: 1. Pregnant or lactating (nursing women) women. 2. Patients with relapsed AML with t(15:17). 3. HIV infection. 4. Active hepatitis B or hepatitis C infection. 5. Concurrent use of systemic steroids or immunosuppressant medications. Recent or current use of inhaled steroids or physiologic replacement with hydrocortisone is not exclusionary. For additional details regarding use of steroids while on study, please see Section 5.5. 6. Any uncontrolled active medical disorder that would preclude participation as outlined. 7. Subjects with signs or symptoms indicative of CNS involvement. A CNS evaluation should be performed as clinically appropriate to rule out CNS involvement. 8. Known history of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40). 9. Class III/IV cardiovascular disability according to the New York Heart Association Classification (see Appendix 3). 10. Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, and unrelated to leukemia or previous leukemia treatment. 11. Subjects with clinically apparent arrhythmia, or arrhythmias that are not stable on medical management, within 2 weeks of the Screening/Enrollment visit. 12. Patients with any prior history of myeloproliferative neoplasm. 13. Patients with the JAK2 V617F mutation by PCR or next generation sequencing.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
CART123 cells; cyclophosphamide; fludarabine
CART123 cells following lymphodepleting chemotherapy in patients with relapsed/refractory AML. Subjects will be treated with a split dosing approach of CART123 cells (10% Day 0; 30% Day 1; 60% Day 2) for Cohort 1a/1b or a single IV administration of CART123 cells for Cohort 2. The total dose administered to each subject will be based on body weight obtained at the time of apheresis. Thus, the target total transduced dose, preceded by lymphodepleting chemotherapy, is 1-2x10^6 CART123 cells/kg for Cohort 1a, 5x10^6 CART123 cells/kg for Cohort 1b, or 2x10^6 CART-123 cells/kg for Cohort 2. The protocol-specified minimum acceptable dose for infusion is 1x10^5 CART123 cells/kg.

Locations

Country Name City State
United States University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety profile of CART123 cells by monitoring the frequency and severity of adverse events assessed by the National Cancer Institute (NCI) - Common Toxicity Criteria (v5.0) Assess the safety of CART123 cells in AML subjects following lymphodepletion with cyclophosphamide + fludarabine. 5 years
Primary Evaluate the percentage of manufacturing products that do not meet release criteria for vector transduction efficiency, T cell product purity, viability, sterility. Evaluate the percentage of manufacturing products that do not meet release criteria for vector transduction efficiency, T cell product purity, viability, sterility. 5 year
Secondary Estimation of CART123 efficacy by evaluation of OS and PFS of subjects at protocol defined intervals which receive at least one infusion of CART123 cells Estimate the efficacy of at least 1 dose of CART123 cells in AML subjects 15 years
Secondary Overall Survival (OS) as percent of subjects surviving at protocol defined time points. Overall survival (OS) and progression-free survival (PFS) 15 years
Secondary Progression-free survival (PFS) as percent of subjects surviving without disease progression at protocol defined time points 15 years
Secondary Duration of response (DOR) Duration of response (DOR) 15 years
Secondary Necessity of rescue bone marrow transplant Need for rescue allogeneic hematopoietic cell transplantation (alloHCT) 15 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02204085 - A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Recruiting NCT06125652 - Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) Phase 1/Phase 2
Recruiting NCT05105152 - PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML Phase 1
Recruiting NCT05597306 - Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT04898894 - Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia Phase 1
Recruiting NCT05546580 - Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) Phase 1
Recruiting NCT03957915 - Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia Early Phase 1
Recruiting NCT05317403 - Venetoclax to Augment Epigenetic Modification and Chemotherapy Phase 1
Recruiting NCT04867928 - Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia Phase 2
Completed NCT04402541 - Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Not yet recruiting NCT04716452 - Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT05211570 - AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Terminated NCT03690154 - A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML Phase 1
Not yet recruiting NCT06459024 - Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Not yet recruiting NCT05854966 - CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT05735184 - A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML Phase 1
Recruiting NCT05124288 - Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways
Recruiting NCT05506332 - Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT05949125 - Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 Phase 1
Recruiting NCT06128044 - CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1